TOWA PHARMACEUTICAL CO.,LTD. [4553.T]

TOKYO, May 14 (Pulse News Wire) – Towa Pharmaceutical Co., Ltd. (4553.T) reported consolidated results for fiscal year 2026 ending March.

Revenue was ¥270 billion (+5.4% YoY). operating profit was ¥23,102 million (-0.6%). net profit attributable to shareholders was ¥5,250 million (-72.3%).

Total assets stood at ¥480 billion with an equity ratio of 37.5%. The company declared an annual dividend of ¥40 per share. The full-year forecast for the current fiscal year is revenue of ¥300 billion (+11.1%).

Financial results — FY2026/3 (consolidated)

MetricCurrentYoY
Revenue¥273,710M+5.4%
Operating profit¥23,102M-0.6%
Net profit¥5,250M-72.3%

Next period forecast

Revenue

¥304,000M

+11.1%

Op. profit

¥32,000M

+38.5%

Net profit

¥21,500M

+309.5%

Source: TDNet filing · Figures in millions of yen

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.